Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol 2020; 21: 271–82—In this Article, the fifth sentence of the third paragraph of the Discussion should read “Additionally, potentially less responsive cancers such as ovarian carcinomas and neuroendocrine tumours were much less represented in the integrated analysis of larotrectinib than that of entrectinib11 and the generally more responsive subtype of infantile fibrosarcoma was not represented at all in the entrectinib analysis.” This correction has been made to the online version as of Sept 27, 2021.
[Corrections] Correction to Lancet Oncol 2020; 21: 271–82
Leggi l'articolo originale